This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Teijin Limited. Active years: 1997-1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hachioji, JP (1997)
- Hino, JP (1998)
Company Filing History:
Years Active: 1997-1998
Title: Shiro Kondo: Innovator in Pharmaceutical Compositions
Introduction
Shiro Kondo is a notable inventor based in Hachioji, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new compounds for treating various medical conditions. With a total of 2 patents, Kondo's work has the potential to impact the healthcare industry positively.
Latest Patents
Kondo's latest patents focus on innovative pharmaceutical compositions. One of his key inventions is a protecting agent for organ or tissue, specifically involving 2-arylthiazole derivatives. This composition is designed for treating gout or hyperuricemia, utilizing the 2-arylthiazole derivatives as an active ingredient. The derivatives are represented by a specific chemical formula, which includes various groups such as pyridyl, thienyl, furyl, naphthyl, or phenyl.
Career Highlights
Shiro Kondo is associated with Teijin Limited, a company known for its advancements in various technological fields. His work at Teijin has allowed him to explore and develop innovative solutions in pharmaceuticals, contributing to the company's reputation for excellence in research and development.
Collaborations
Kondo has collaborated with notable colleagues, including Hisashi Fukushima and Masaichi Hasegawa. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Shiro Kondo's contributions to pharmaceutical compositions demonstrate his commitment to advancing medical science. His innovative work, particularly in the area of 2-arylthiazole derivatives, showcases the potential for new treatments in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
